Skip to main content
Erschienen in: Indian Journal of Hematology and Blood Transfusion 2/2024

30.08.2023 | ORIGINAL ARTICLE

Prognostic Factors and Outcomes of Early-Stage Hodgkin’s Lymphoma: Multi-Institutional Data From South India

verfasst von: Lakshmi Sandhya Singuluri, Perumal Kalaiyarasi Jayachandran, Luxitaa Goenka, Praveen Kumar Shenoy, Krishna Kumar Rathnam, Arun Seshachalam, Nikita Mehra, Mummoorthy Ram Kumar, Murugan Mangai Suseela, Vineetha Raghavan, Chandran K. Nair, Biswajit Dubashi, Manikandan Dhanushkodi, Prasanth Ganesan

Erschienen in: Indian Journal of Hematology and Blood Transfusion | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

Early-stage Hodgkin's lymphoma (ESHL) is highly curable, usually with a combination of chemotherapy and radiation. Real-world data may show differences in survival and prognostic factors when compared to clinical trials. There is limited published literature on ESHL from India. The data on the baseline characters, treatment, and outcomes of patients with ESHL (stage IA, IB, and IIA) were obtained from five institutions' medical records and entered in a common database. Event-free survival (EFS) and overall survival (OS) were estimated using the Kaplan Meier method, and cox-regression analysis was used to identify prognostic factors. There were 258 patients [median age was 37 (18–75) years; [males:160 (62%); stage I: 41%; B symptoms: 17 (6%); bulky disease:19 (15%)] treated between 2000 and 2020 who were evaluable. The common chemotherapies used were ABVD [N = 180 (70%)], COPP-ABVD hybrid [N = 52 (21%)], and COPP [N = 14 (5%)]. Median number of cycles were 4 (2–8) and 93 (47%) received radiation at end of treatment. After a median follow-up of 60 months, the 5 years EFS was 87% and OS was 92%. On multivariate analysis, the following factors adversely affected the EFS: Male gender [hazard ratio (HR) = 2.23, P = 0.02] and Hemoglobin < 10.5g/dL [hazard ration (HR) = 2.20, P = 0.02], and the following adversely affected the OS: Hemoglobin < 10.5g/dL [hazard ratio (HR) = 4.05, P = 0.001], Male gender [hazard ratio (HR) = 3.59, P = 0.004], Stage 2 [hazard ratio (HR) = 2.65, P = 0.002] and ECOG PS (2–3) [hazard ratio (HR) = 3.35, P = 0.01]. Using the hemoglobin, stage and gender a 3-item prognostic score could identify patients with very good outcomes (score 0; 5 years OS:100%) and poor outcomes (score 3; 5 years OS; 49%). This is one of the first multi-center real-world data exclusively focusing on ESHL from India. Though the survival of the entire population was good, there are subsets of patients who have poor outcomes, which may be identified using simple parameters. These parameters need validation in a larger dataset.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Canellos GP, Rosenberg SA, Friedberg JW, Lister TA, Devita VT (2014) Treatment of Hodgkin lymphoma: a 50-year perspective. J Clin Oncol Off J Am Soc Clin Oncol 32(3):163–168CrossRef Canellos GP, Rosenberg SA, Friedberg JW, Lister TA, Devita VT (2014) Treatment of Hodgkin lymphoma: a 50-year perspective. J Clin Oncol Off J Am Soc Clin Oncol 32(3):163–168CrossRef
2.
Zurück zum Zitat Canellos GP (2005) Chemotherapy alone for early Hodgkin’s lymphoma: an emerging option. J Clin Oncol Off J Am Soc Clin Oncol 23(21):4574–4576CrossRef Canellos GP (2005) Chemotherapy alone for early Hodgkin’s lymphoma: an emerging option. J Clin Oncol Off J Am Soc Clin Oncol 23(21):4574–4576CrossRef
3.
Zurück zum Zitat Bröckelmann PJ, Sasse S, Engert A (2018) Balancing risk and benefit in early-stage classical Hodgkin lymphoma. Blood 131(15):1666–1678CrossRefPubMed Bröckelmann PJ, Sasse S, Engert A (2018) Balancing risk and benefit in early-stage classical Hodgkin lymphoma. Blood 131(15):1666–1678CrossRefPubMed
4.
Zurück zum Zitat Myint ZW, Shrestha R, Siddiqui S, Slone S, Huang B, Ramlal R et al (2020) Ten-year survival outcomes for patients with early stage classical Hodgkin lymphoma: an analysis from Kentucky Cancer Registry. Hematol Oncol Stem Cell Ther 13(1):17–22CrossRefPubMed Myint ZW, Shrestha R, Siddiqui S, Slone S, Huang B, Ramlal R et al (2020) Ten-year survival outcomes for patients with early stage classical Hodgkin lymphoma: an analysis from Kentucky Cancer Registry. Hematol Oncol Stem Cell Ther 13(1):17–22CrossRefPubMed
5.
Zurück zum Zitat Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI sponsored international working group. J Clin Oncol Off J Am Soc Clin Oncol. 17(4):1244CrossRef Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI sponsored international working group. J Clin Oncol Off J Am Soc Clin Oncol. 17(4):1244CrossRef
6.
Zurück zum Zitat Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Müeller SP et al (2014) Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group. J Clin Oncol Off J Am Soc Clin Oncol 32(27):3048–58CrossRef Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Müeller SP et al (2014) Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group. J Clin Oncol Off J Am Soc Clin Oncol 32(27):3048–58CrossRef
7.
Zurück zum Zitat Hasenclever D, Diehl V (1998) A prognostic score for advanced Hodgkin’s disease International. Prognostic factors project on advanced Hodgkin’s disease. N Engl J Med 339(21):1506–14CrossRefPubMed Hasenclever D, Diehl V (1998) A prognostic score for advanced Hodgkin’s disease International. Prognostic factors project on advanced Hodgkin’s disease. N Engl J Med 339(21):1506–14CrossRefPubMed
8.
Zurück zum Zitat Ganesan P, Dhanushkodi M, Ganesan TS, Radhakrishnan V, Kannan K, Sundersingh S et al (2019) Prognostic utility of the IPS 3 score for predicting outcomes in advanced Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 19(2):116–122CrossRefPubMed Ganesan P, Dhanushkodi M, Ganesan TS, Radhakrishnan V, Kannan K, Sundersingh S et al (2019) Prognostic utility of the IPS 3 score for predicting outcomes in advanced Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 19(2):116–122CrossRefPubMed
9.
Zurück zum Zitat Van Belle SJP (2004) What is the value of hemoglobin as a prognostic and predictive factor in cancer? Eur J Cancer Suppl [Internet] 2(2):11–9CrossRef Van Belle SJP (2004) What is the value of hemoglobin as a prognostic and predictive factor in cancer? Eur J Cancer Suppl [Internet] 2(2):11–9CrossRef
10.
Zurück zum Zitat Kishore S, Singh M, Jain B, Verma N, Gawande K, Kishore S et al (2020) A study to assess prevalence of anaemia among beneficiaries of Anaemia Mukt Bharat Campaign in Uttarakhand. J Fam Med Prim Care [Internet] 9(3):1691CrossRef Kishore S, Singh M, Jain B, Verma N, Gawande K, Kishore S et al (2020) A study to assess prevalence of anaemia among beneficiaries of Anaemia Mukt Bharat Campaign in Uttarakhand. J Fam Med Prim Care [Internet] 9(3):1691CrossRef
11.
Zurück zum Zitat André MPE, Girinsky T, Federico M, Reman O, Fortpied C, Gotti M et al (2017) Early positron emission tomography response-adapted treatment in stage I and II Hodgkin Lymphoma: final results of the randomized EORTC/LYSA/FIL H10 Trial. J Clin Oncol Off J Am Soc Clin Oncol 35(16):1786–1794CrossRef André MPE, Girinsky T, Federico M, Reman O, Fortpied C, Gotti M et al (2017) Early positron emission tomography response-adapted treatment in stage I and II Hodgkin Lymphoma: final results of the randomized EORTC/LYSA/FIL H10 Trial. J Clin Oncol Off J Am Soc Clin Oncol 35(16):1786–1794CrossRef
12.
Zurück zum Zitat Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P et al (2015) Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med 372(17):1598–1607CrossRefPubMed Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P et al (2015) Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med 372(17):1598–1607CrossRefPubMed
13.
Zurück zum Zitat Chohan KL, Young JR, Lester S, AlhajMoustafa M, Rosenthal A, Tun HW et al (2022) A real-world study of combined modality therapy for early-stage Hodgkin lymphoma: too little treatment impacts outcome. Blood Adv 6(14):4241–4250CrossRefPubMedPubMedCentral Chohan KL, Young JR, Lester S, AlhajMoustafa M, Rosenthal A, Tun HW et al (2022) A real-world study of combined modality therapy for early-stage Hodgkin lymphoma: too little treatment impacts outcome. Blood Adv 6(14):4241–4250CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Cuccaro A, Bartolomei F, Cupelli E, Hohaus S (2014) Prognostic factors in Hodgkin lymphoma. Mediterr J Hematol Infect Dis [Internet] 6(1):e2014053CrossRefPubMed Cuccaro A, Bartolomei F, Cupelli E, Hohaus S (2014) Prognostic factors in Hodgkin lymphoma. Mediterr J Hematol Infect Dis [Internet] 6(1):e2014053CrossRefPubMed
15.
Zurück zum Zitat Horesh N, Horowitz NA (2014) Does gender matter in Non-Hodgkin lymphoma? Differences in epidemiology, clinical behavior, and Therapy. Rambam Maimonides Med J [Internet] 5(4):e0038CrossRefPubMed Horesh N, Horowitz NA (2014) Does gender matter in Non-Hodgkin lymphoma? Differences in epidemiology, clinical behavior, and Therapy. Rambam Maimonides Med J [Internet] 5(4):e0038CrossRefPubMed
17.
Zurück zum Zitat Klimm B, Goergen H, Fuchs M, von Tresckow B, Böll B, Meissner J et al (2013) Impact of risk factors on outcomes in early-stage Hodgkin’s lymphoma: an analysis of international staging definitions. Ann Oncol Off J Eur Soc Med Oncol 24(12):3070–3076CrossRef Klimm B, Goergen H, Fuchs M, von Tresckow B, Böll B, Meissner J et al (2013) Impact of risk factors on outcomes in early-stage Hodgkin’s lymphoma: an analysis of international staging definitions. Ann Oncol Off J Eur Soc Med Oncol 24(12):3070–3076CrossRef
18.
Zurück zum Zitat Ganesan P, Kumar L, Raina V, Sharma A, Bakhshi S, Sreenivas V et al (2011) Hodgkin’s lymphoma–long-term outcome: an experience from a tertiary care cancer center in North India. Ann Hematol 90(10):1153–1160CrossRefPubMed Ganesan P, Kumar L, Raina V, Sharma A, Bakhshi S, Sreenivas V et al (2011) Hodgkin’s lymphoma–long-term outcome: an experience from a tertiary care cancer center in North India. Ann Hematol 90(10):1153–1160CrossRefPubMed
19.
Zurück zum Zitat Maddi RN, Linga VG, Iyer KK, Chowdary JS, Gundeti S, Digumarti R et al (2015) Clinical profile and outcome of adult Hodgkin lymphoma: experience from a tertiary care institution. Indian J Med Paediatr Oncol Off J Indian Soc Med Paediatr Oncol 36(4):255–260CrossRef Maddi RN, Linga VG, Iyer KK, Chowdary JS, Gundeti S, Digumarti R et al (2015) Clinical profile and outcome of adult Hodgkin lymphoma: experience from a tertiary care institution. Indian J Med Paediatr Oncol Off J Indian Soc Med Paediatr Oncol 36(4):255–260CrossRef
20.
Zurück zum Zitat Bhurani D, Nair R, Rajappa S, Rao SA, Sridharan N, Boya RR et al (2021) Real-world outcomes of hodgkin lymphoma: a multi-centric registry from India. Front Oncol 11:799948CrossRefPubMed Bhurani D, Nair R, Rajappa S, Rao SA, Sridharan N, Boya RR et al (2021) Real-world outcomes of hodgkin lymphoma: a multi-centric registry from India. Front Oncol 11:799948CrossRefPubMed
21.
Zurück zum Zitat Diefenbach CS, Li H, Hong F, Gordon LI, Fisher RI, Bartlett NL et al (2015) Evaluation of the international prognostic score (IPS-7) and a simpler prognostic score (IPS-3) for advanced Hodgkin lymphoma in the modern era. Br J Haematol 171(4):530–538CrossRefPubMedPubMedCentral Diefenbach CS, Li H, Hong F, Gordon LI, Fisher RI, Bartlett NL et al (2015) Evaluation of the international prognostic score (IPS-7) and a simpler prognostic score (IPS-3) for advanced Hodgkin lymphoma in the modern era. Br J Haematol 171(4):530–538CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Sasse S, Goergen H, Plütschow A, Böll B, Eichenauer DA, Fuchs M et al (2018) Outcome of patients with early-stage infradiaphragmatic hodgkin lymphoma: a comprehensive analysis from the German Hodgkin study group. J Clin Oncol Off J Am Soc Clin Oncol 36(25):2603–2611CrossRef Sasse S, Goergen H, Plütschow A, Böll B, Eichenauer DA, Fuchs M et al (2018) Outcome of patients with early-stage infradiaphragmatic hodgkin lymphoma: a comprehensive analysis from the German Hodgkin study group. J Clin Oncol Off J Am Soc Clin Oncol 36(25):2603–2611CrossRef
23.
Zurück zum Zitat Rigacci L, Puccini B, Zinzani PL, Biggi A, Castagnoli A, Merli F et al (2015) The prognostic value of positron emission tomography performed after two courses (INTERIM-PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: a multicentric study by the fondazione italiana linfomi (FIL). Am J Hematol 90(6):499–503CrossRefPubMed Rigacci L, Puccini B, Zinzani PL, Biggi A, Castagnoli A, Merli F et al (2015) The prognostic value of positron emission tomography performed after two courses (INTERIM-PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: a multicentric study by the fondazione italiana linfomi (FIL). Am J Hematol 90(6):499–503CrossRefPubMed
24.
Zurück zum Zitat Barrington SF, Phillips EH, Counsell N, Hancock B, Pettengell R, Johnson P et al (2019) Positron emission tomography score has greater prognostic significance than pretreatment risk stratification in early-stage hodgkin lymphoma in the UK RAPID study. J Clin Oncol Off J Am Soc Clin Oncol 37(20):1732–1741CrossRef Barrington SF, Phillips EH, Counsell N, Hancock B, Pettengell R, Johnson P et al (2019) Positron emission tomography score has greater prognostic significance than pretreatment risk stratification in early-stage hodgkin lymphoma in the UK RAPID study. J Clin Oncol Off J Am Soc Clin Oncol 37(20):1732–1741CrossRef
25.
Zurück zum Zitat Cottereau AS, Versari A, Loft A, Casasnovas O, Bellei M, Ricci R et al (2018) Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial. Blood 131(13):1456–1463CrossRefPubMed Cottereau AS, Versari A, Loft A, Casasnovas O, Bellei M, Ricci R et al (2018) Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial. Blood 131(13):1456–1463CrossRefPubMed
26.
Zurück zum Zitat Fuchs M, Goergen H, Kobe C, Kuhnert G, Lohri A, Greil R et al (2019) Positron emission tomography-guided treatment in early-stage favorable hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin study group. J Clin Oncol Off J Am Soc Clin Oncol 37(31):2835–2845CrossRef Fuchs M, Goergen H, Kobe C, Kuhnert G, Lohri A, Greil R et al (2019) Positron emission tomography-guided treatment in early-stage favorable hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin study group. J Clin Oncol Off J Am Soc Clin Oncol 37(31):2835–2845CrossRef
Metadaten
Titel
Prognostic Factors and Outcomes of Early-Stage Hodgkin’s Lymphoma: Multi-Institutional Data From South India
verfasst von
Lakshmi Sandhya Singuluri
Perumal Kalaiyarasi Jayachandran
Luxitaa Goenka
Praveen Kumar Shenoy
Krishna Kumar Rathnam
Arun Seshachalam
Nikita Mehra
Mummoorthy Ram Kumar
Murugan Mangai Suseela
Vineetha Raghavan
Chandran K. Nair
Biswajit Dubashi
Manikandan Dhanushkodi
Prasanth Ganesan
Publikationsdatum
30.08.2023
Verlag
Springer India
Erschienen in
Indian Journal of Hematology and Blood Transfusion / Ausgabe 2/2024
Print ISSN: 0971-4502
Elektronische ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-023-01692-9

Weitere Artikel der Ausgabe 2/2024

Indian Journal of Hematology and Blood Transfusion 2/2024 Zur Ausgabe

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.